Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Mary Alice Abbott

Clinical Genetics (M.D.) Worcester, MA Medical Doctor

NPI 1982799417 CMS profile 505340

55 Lake Ave N, Worcester, MA 01655

Open in the dashboard

General payments

$22,120

30 records reported · program years 2019–2024

Research payments

$5,229

Paid to them · 10 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$80,805 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Mary Alice Abbott of Worcester, MA is reported in the CMS Open Payments database as having received $22,120 across 30 general payments and $5,229 in research payments paid to them. Separately, studies naming them as principal investigator received $80,805 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 86th percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $750 2
2023 General $1,000 2
2023 Research $250 1
2022 General $3,576 3
2021 General $4,510 2
2020 General $6,133 9
2020 Research $2,172 4
2019 General $6,901 14
2019 Research $2,057 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Alice Abbott
  • Clinical Genetics (M.D.) median
  • Middle half of Clinical Genetics (M.D.)
  • National median

In program year 2025, general payments to Mary Alice Abbott were reported at $0. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.

Show as a table
Year Mary Alice Abbott Clinical Genetics (M.D.) median Middle half National median
2019 $6,901 $130 $24–$2,691 $163
2020 $6,133 $126 $30–$3,700 $114
2021 $4,510 $185 $30–$3,777 $132
2022 $3,576 $136 $44–$2,749 $149
2023 $1,000 $196 $55–$5,220 $160
2024 $0 $165 $46–$3,171 $164
2025 $0 $255 $85–$3,583 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Genzyme Corporation $22,120 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $17,586 5 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,051 5 payments
  3. Travel and Lodging $1,674 8 payments
  4. Food and Beverage $809 12 payments
Products named General payments · program years 2019–2024
  1. LUMIZYME Genetic Disease $11,941 14 payments
  2. LUMIZYME Rare Disease Genetics $5,983 8 payments
  3. NO PRODUCT DISCUSSED $919 6 payments
  4. NEXVIAZYME $500 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Genzyme Corporation $5,229 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Pediatric Medicine: 38

Drug cost

$768,736

Median for Pediatric Medicine: $2,769

Branded share of claims

100%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nexviazyme Avalglucosidase Alfa-Ngpt Brand 12 $768,736

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$1,537

Medicare's payments for the services billed

Medicare patients

13

Average age 60

Services billed

21

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Ischemic heart disease 0%
Depression 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Genetics (M.D.) in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record